M&As this week: Signal Genetics, Karos Health, Fresenius Medical Care (FMC)

3 November 2016 (Last Updated November 3rd, 2016 18:30)

Molecular diagnostic company, Signal Genetics, has agreed to merge with Miragen Therapeutics (miRagen) to form a biopharmaceutical company that will develop proprietary micro RNA-targeted therapeutics for haematological malignancies and pathological fibrosis and cardiovascular and neurodegenerative diseases.

Molecular diagnostic company, Signal Genetics, has agreed to merge with Miragen Therapeutics (miRagen) to form a biopharmaceutical company that will develop proprietary micro RNA-targeted therapeutics for haematological malignancies and pathological fibrosis and cardiovascular and neurodegenerative diseases.

Pursuant to the definitive merger agreement, the stockholders of miRagen will hold 96% of Signal’s outstanding common stock on a fully-diluted basis, subject to certain approvals.

Health care informatics company, Karos Health, will be acquired by Vital Images allowing the companies to offer robust imaging and informatics solution set to their customers and OEM partners.

"The stockholders of miRagen will hold 96% of Signal’s outstanding common stock."

In a move to expand its business in extracorporeal organ support area, dialysis-related products and services provider, Fresenius Medical Care (FMC), has announced its intention to acquire Xenios from ZFHN Zukunftsfonds Heilbronn GmbH, a private venture capitalist based in Germany.

Xenios develops minimally invasive devices for lung and heart diseases.

The deal will be completed before the end of 2016, subject to cartel authority approvals.